Most joint complaints in sports medicine follow a predictable arc—an identifiable mechanism, swelling, imaging, and recovery. But what happens when that arc breaks?

In this opening episode of the CATCH-TGCT series, we explore the early clinical moments when tenosynovial giant cell tumor (TGCT)—a rare but locally aggressive synovial tumor—first intersects with care. Often presenting with symptoms that mimic common injuries, TGCT blends seamlessly into the everyday landscape of sports medicine, contributing to diagnostic delays that can stretch well beyond a year.

Joined by orthopedic sports medicine surgeon Dr. Ryan Freshman (UC Davis), this conversation brings listeners to the true front line of diagnosis: the initial clinical encounter. Here, the working assumption is almost always mechanical injury—and for good reason. But as Dr. Freshman explains, it’s the subtle deviations from expected recovery patterns that should prompt a shift in thinking.

Key clinical insights emerge:

- Persistent symptoms beyond six weeks should trigger reconsideration—and imaging becomes essential, not optional

- Recurrent, atraumatic joint effusions that do not respond to conservative care are a critical red flag

- When symptom patterns don’t align with mechanism, clinicians must broaden the differential

Through real-world clinical reasoning, this episode highlights the “Gestalt” that develops with experience—recognizing when something simply doesn’t fit. It also reinforces practical, actionable habits: clearly communicating suspicion in MRI orders, directly engaging radiologists, and most importantly, listening carefully to the patient narrative.

The episode then expands to a systems-level perspective with musculoskeletal oncologist Dr. R. Lor Randall, who reflects on what diagnostic delay looks like from the other end of the journey. While TGCT is often slow-growing, prolonged delays can lead to structural joint damage and more complex treatment pathways. His message is clear: if symptoms persist beyond three to six months, clinicians must pause and reconsider the diagnosis.

Together, these perspectives reveal a unifying theme—TGCT is not missed because it is invisible, but because it appears familiar.

This episode challenges clinicians to rethink time as a diagnostic signal. At some point, the question shifts from “What caused this?” to “Why hasn’t this resolved?”

Because when duration outweighs mechanism, recognition becomes possible—and early action can change everything that follows.